3 European Penny Stocks With Market Caps Over €30M

As the pan-European STOXX Europe 600 Index has recently edged higher, buoyed by hopes of increased government spending yet tempered by trade tensions, investors are keenly observing opportunities within the market. Penny stocks, a term that may seem outdated but remains relevant in highlighting smaller or less-established companies, can offer significant value when supported by strong financials. By focusing on those with robust balance sheets and potential for growth, investors may uncover promising opportunities among European penny stocks.

Top 10 Penny Stocks In Europe

Click here to see the full list of 433 stocks from our European Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

ABIONYX Pharma (ENXTPA:ABNX)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: ABIONYX Pharma SA is a biotech company focused on discovering and developing therapies for renal and ophthalmological diseases, with a market cap of €44.59 million.

Operations: The company generates revenue of €4.6 million from its research and development activities in innovative medicine development.

Market Cap: €44.59M

ABIONYX Pharma, a biotech company with a market cap of €44.59 million, operates in the realm of renal and ophthalmological therapies. Despite generating €4.6 million in revenue from innovative medicine development, the company remains unprofitable with increasing losses over the past five years at 18.6% annually. It has sufficient cash runway for more than a year and recently raised additional capital to extend this runway further. While ABIONYX's seasoned management and board offer stability, its negative return on equity (-46.57%) reflects ongoing financial challenges amidst forecasted revenue growth of 42.47% per year.

• Unlock comprehensive insights into our analysis of ABIONYX Pharma stock in this financial health report.
• Examine ABIONYX Pharma's earnings growth report to understand how analysts expect it to perform.

Lohilo Foods (NGM:LOHILO)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Lohilo Foods AB (publ) is a Swedish food company with international operations, and it has a market cap of SEK59.89 million.

Operations: The company generates revenue primarily from its Own Trademarks at SEK176.55 million and Distributed Trademarks at SEK28.62 million.

Market Cap: SEK59.89M

Lohilo Foods AB, with a market cap of SEK59.89 million, has shown revenue growth, reporting SEK205.17 million for 2024 compared to SEK182.13 million the previous year. Despite being unprofitable, it reduced its net loss significantly from SEK29.12 million to SEK2.28 million year-on-year and improved its debt-to-equity ratio from 216.3% to 79.8% over five years, though it still holds a high net debt-to-equity ratio of 55.9%. The company maintains a positive free cash flow and has sufficient cash runway for over three years despite not covering short-term liabilities with short-term assets (SEK31.4M vs SEK55.4M).

• Take a closer look at Lohilo Foods' potential here in our financial health report.
• Gain insights into Lohilo Foods' past trends and performance with our report on the company's historical track record.

Transferator (NGM:TRAN A)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Transferator AB (publ) is a public private equity and venture capital firm with a market cap of SEK233.45 million.

Operations: Transferator generates revenue of SEK55.17 million from its operations in Sweden.

Market Cap: SEK233.45M

Transferator AB, with a market cap of SEK233.45 million, has demonstrated robust financial health despite recent sales decline to SEK16.41 million in Q4 2024 from SEK21.28 million the previous year. The firm has reduced its debt-to-equity ratio over five years and maintains more cash than total debt, indicating strong liquidity. Its earnings growth of 69.9% last year outpaced the industry average, and it boasts an outstanding return on equity of 74.6%. However, its dividend yield is unsustainable by current earnings and share price volatility remains high compared to peers in Sweden's market.

• Get an in-depth perspective on Transferator's performance by reading our balance sheet health report here.
• Evaluate Transferator's historical performance by accessing our past performance report.

Seize The Opportunity

• Gain an insight into the universe of 433 European Penny Stocks by clicking here.
• Seeking Other Investments? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com